Compositions and methods for enhancing drug delivery across and into epithelial tissues
First Claim
1. A method of targeting a compound to a gastrointestinal epithelium of an animal, the method comprising administering to the gastrointestinal epithelium a conjugate comprising the compound and a delivery-enhancing transporter,wherein:
- i. the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidino or amidino moieties; and
ii. the conjugate has a structure selected from the group consisting of structures 3, 4, 5, and 6 as follows;
wherein;
R1 comprises the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
A is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is S, O, NR6 or CR7R8;
R5 is H, OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
R7 is hydrogen or an alkyl;
R8 is hydrogen or an alkyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10, thereby increasing delivery of the conjugate into the gastrointestinal epithelium compared to delivery of the compound in the absence of the delivery-enhancing transporter.
3 Assignments
0 Petitions
Accused Products
Abstract
This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
-
Citations
88 Claims
-
1. A method of targeting a compound to a gastrointestinal epithelium of an animal, the method comprising administering to the gastrointestinal epithelium a conjugate comprising the compound and a delivery-enhancing transporter,
wherein: -
i. the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidino or amidino moieties; and
ii. the conjugate has a structure selected from the group consisting of structures 3, 4, 5, and 6 as follows;
wherein;
R1 comprises the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
A is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is S, O, NR6 or CR7R8;
R5 is H, OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
R7 is hydrogen or an alkyl;
R8 is hydrogen or an alkyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10, thereby increasing delivery of the conjugate into the gastrointestinal epithelium compared to delivery of the compound in the absence of the delivery-enhancing transporter. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 34, 35, 36, 37, 38, 39)
wherein; R1 comprises the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
A is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is S, O, NR6 or CR7R8;
R5 is H, OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
R7 and R8 are independently selected from hydrogen or alkyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10.
-
-
35. The method of claim 34, wherein X is selected from the group consisting of —
- C(O)O—
, —
C(O)NH—
, —
OC(O)NH—
, —
S—
S—
, —
C(S)O—
, —
C(S)NH—
, —
NHC(O)NH—
, —
SO2NH—
, —
SONH—
, phosphate, phosphonate, phosphinate, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
- C(O)O—
-
36. The method of claim 34, wherein the conjugate comprises structure 3, Y is NH, and R2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.
-
37. The method of claim 34, wherein R2 is benzyl;
- k, m, and n are each 1, and X is —
OC(O)—
.
- k, m, and n are each 1, and X is —
-
38. The method of claim 34, wherein the conjugate comprises structure 4;
- R4 is S;
R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R4 is S;
-
39. The method of claim 34, wherein the conjugate comprises structure 4;
- R5 is NHR6;
R6 is hydrogen, methyl, allyl, butyl or phenyl; and
k and m are each 1.
- R5 is NHR6;
-
29. A method for enhancing delivery of a compound into and across one or more layers of an animal ocular epithelial tissue, the method comprising:
-
administering to the ocular epithelial tissue a conjugate comprising the compound and a delivery-enhancing transporter, wherein;
i. the compound is attached to the delivery-enhancing transporter through a linker, and ii. the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidino or amidino moieties, thereby increasing delivery of the conjugate into and across the ocular epithelial tissue compared to delivery of the compound in the absence of the delivery-enhancing transporter. - View Dependent Claims (30, 31, 32, 33, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 55, 56, 57, 58, 88)
wherein; R1 the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
R3 comprises the delivery-enhancing transporter;
R4 is S, O, NR6 or CR7R8;
R5 is H, OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, arylalkyl, acyl or allyl;
R7 and R8 are independently selected from hydrogen or alkyl; and
k and m are each independently selected from 1 and 2.
-
-
41. The method of claim 40, wherein X is selected from the group consisting of —
- C(O)O—
, —
C(O)NH—
, —
OC(O)NH—
, —
S—
S—
, —
C(S)O—
, —
C(S)NH—
, —
NHC(O)NH—
, —
SO2NH—
, —
SONH—
, phosphate, phosphonate, phosphinate, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
- C(O)O—
-
42. The method of claim 40, wherein R4 is S;
- R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R5 is NHR6; and
-
43. The method of claim 29, wherein the conjugate comprises at least two delivery-enhancing transporters.
-
44. The method of claim 29, wherein the conjugate is administered as an eye drop.
-
45. The method of claim 29, wherein the conjugate is administered as an injection.
-
46. The method of claim 29, wherein the delivery-enhancing transporter comprises a non-peptide backbone.
-
47. The method of claim 29, wherein the delivery-enhancing transporter is not attached to an amino acid sequence to which the delivery enhancing transporter molecule is attached in a naturally occurring protein.
-
48. The method of claim 29, wherein the delivery-enhancing transporter comprises from 5 to 25 guanidino or amidino moieties.
-
49. The method of claim 48, wherein the delivery-enhancing transporter comprises between 7 and 15 guanidino moieties.
-
50. The method of claim 48, wherein the delivery-enhancing transporter comprises at least 6 contiguous guanidino and/or amidino moieties.
-
51. The method of claim 29, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof.
-
52. The method of claim 51, wherein the delivery-enhancing transporter comprises 5 to 25 arginine residues or analogs thereof.
-
55. The method of claim 51, wherein at least 70 percent of the amino acids that comprise the delivery-enhancing transporter are arginines or arginine analogs.
-
56. The method of claim 51, wherein the delivery-enhancing transporter is seven contiguous D-arginines.
-
57. The method of claim 29, wherein the compound is a therapeutic for the disease selected from the group consisting of conjunctivitis, bacterial infections, viral infections, dry eye, and glaucoma.
-
58. The method of claim 29, wherein the compound is selected from the group consisting of antibacterial compounds, antiviral compounds, cyclosporin, ascomycins, and corticosteroids.
-
88. The method of claim 29, wherein the conjugate is transported into an ocular tissue selected from the group consisting of cornea, iris, lens, vitreus, vitreus humor, aqueous humor, sclera, and optic nerve.
- 53. The method of claim wherein at least one arginine is a D-arginine.
-
59. A method of targeting a compound to a gastrointestinal epithelium of an animal, the method comprising administering to the gastrointestinal epithelium a conjugate comprising the compound and a delivery-enhancing transporter,
wherein: -
i. the compound is attached to the delivery-enhancing transporter through a linker;
ii. the compound is a therapeutic for the disease selected from the group consisting of inflammatory bowel disease, colon cancer, ulcerative colitis, gastrointestinal ulcers, constipation and imbalance of salt and water absorption; and
ii. the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidino or amidino moieties, thereby increasing delivery of the conjugate into the gastrointestinal epithelium compared to delivery of the compound in the absence of the delivery-enhancing transporter. - View Dependent Claims (60, 61, 62, 63, 64, 65)
-
-
66. A method for enhancing delivery of a compound into and across one or more layers of an animal epithelial tissue, the method comprising buccally administering a conjugate comprising the compound and a delivery-enhancing transporter, wherein:
-
i. the compound is attached to the delivery-enhancing transporter through a linker; and
ii. the delivery-enhancing transporter comprises fewer than 50 subunits and comprises at least 5 guanidino or amidino moieties, thereby increasing delivery of the conjugate into and across one or more layers of the animal epithelial tissue compared to delivery of the compound in the absence of the delivery-enhancing transporter. - View Dependent Claims (67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)
wherein; R1 comprises the compound;
X is a linkage formed between a functional group on the compound and a terminal functional group on the linking moiety;
Y is a linkage formed from a functional group on the transport moiety and a functional group on the linking moiety;
Ar is an aryl group having the attached radicals arranged in an ortho or para configuration, which aryl group can be substituted or unsubstituted;
A is N or CH;
R2 is hydrogen, alkyl, aryl, acyl, or allyl;
R3 comprises the delivery-enhancing transporter;
R4 is S, O, NR6 or CR7R8;
R5 is H, OH, SH or NHR6;
R6 is hydrogen, alkyl, aryl, acyl or allyl;
R7 is hydrogen or an alkyl;
R8 is hydrogen or an alkyl;
k and m are each independently selected from 1 and 2; and
n is 1 to 10.
-
-
70. The method of claim 69, wherein X is selected from the group consisting of —
- C(O)O—
, —
C(O)NH—
, —
OC(O)NH—
, —
S—
S—
, —
C(S)O—
, —
C(S)NH—
, —
NHC(O)NH—
, —
SO2NH—
, —
SONH—
, phosphate, phosphonate, phosphinate, and CR7R8, wherein R7 and R8 are each independently selected from the group consisting of H and alkyl.
- C(O)O—
-
71. The method of claim 69, wherein the conjugate comprises structure 3, Y is NH, and R2 is methyl, ethyl, propyl, butyl, allyl, benzyl or phenyl.
-
72. The method of claim 69, wherein R2 is benzyl;
- k, m, and n are each 1, and X is —
OC(O)—
.
- k, m, and n are each 1, and X is —
-
73. The method of claim 69, wherein the conjugate comprises structure 4;
- R4 is S;
R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R4 is S;
-
74. The method of claim 69, wherein the conjugate comprises structure 4;
- R5 is NHR6;
R6 is hydrogen, methyl, allyl, butyl or phenyl; and
k and m are each 1.
- R5 is NHR6;
-
75. The method of claim 69, wherein the conjugate comprises structure 6, R4 is S;
- R5 is NHR6; and
R6 is hydrogen, methyl, allyl, butyl or phenyl.
- R5 is NHR6; and
-
76. The method of claim 66, wherein the conjugate comprises at least two delivery-enhancing transporters.
-
77. The method of claim 69, wherein the delivery-enhancing transporter comprises a non-peptide backbone.
-
78. The method of claim 66, wherein the delivery-enhancing transporter is not attached to an amino acid sequence to which the delivery enhancing transporter molecule is attached in a naturally occurring protein.
-
79. The method of claim 66, wherein the delivery-enhancing transporter comprises from 5 to 25 guanidino or amidino moieties.
-
80. The method of claim 66, wherein the delivery-enhancing transporter comprises between 7 and 15 guanidino moieties.
-
81. The method of claim 66, wherein the delivery-enhancing transporter comprises at least 6 contiguous guanidino and/or amidino moieties.
-
82. The method of claim 66, wherein the delivery-enhancing transporter consists essentially of 5 to 50 amino acids, at least 50 percent of which amino acids are arginines or analogs thereof.
-
83. The method of claim 66, wherein the delivery-enhancing transporter comprises 5 to 25 arginine residues or analogs thereof.
-
84. The method of claim 83, wherein at least one arginine is a D-arginine.
-
85. The method of claim 84, wherein all of the arginines are D-arginines.
-
86. The method of claim 82, wherein at least 70 percent of the amino acids that comprise the delivery-enhancing transporter are arginines or arginine analogs.
-
87. The method of claim 66, wherein the delivery-enhancing transporter is seven contiguous D-arginines.
Specification